Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
0(0%)
Results Posted
67%(6 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_2
1
8%
Ph phase_3
4
33%
Ph phase_4
3
25%
Ph not_applicable
2
17%

Phase Distribution

0

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
4(40.0%)
Phase 4Post-market surveillance
3(30.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(9)
Terminated(2)
Other(1)

Detailed Status

Completed9
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
81.8%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (10.0%)
Phase 34 (40.0%)
Phase 43 (30.0%)
N/A2 (20.0%)

Trials by Status

terminated217%
completed975%
unknown18%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_4

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

NCT04159519
completednot_applicable

U-LABA/ICS Effects on Exercise Performance, Formoterol

NCT06105671
completedphase_3

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

NCT03015259
terminatedphase_2

Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

NCT01432080
completedphase_3

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

NCT03468790
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04159519Phase 4

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Completed
NCT06105671Not Applicable

U-LABA/ICS Effects on Exercise Performance, Formoterol

Completed
NCT03015259Phase 3

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

Completed
NCT01432080Phase 2

Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant

Terminated
NCT03468790Phase 3

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Completed
NCT02546297Phase 4

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Unknown
NCT02157935Phase 3

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

Completed
NCT01218399Not Applicable

Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations

Completed
NCT01712854Phase 4

Effects of Symbicort on the Ventilatory Kinematics

Terminated
NCT01360021Phase 3

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

Completed
NCT00812682

Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler

Completed
NCT00573222

Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12